vs
Side-by-side financial comparison of SOLESENCE, INC. (SLSN) and STRATA Skin Sciences, Inc. (SSKN). Click either name above to swap in a different company.
SOLESENCE, INC. is the larger business by last-quarter revenue ($12.5M vs $9.3M, roughly 1.3× STRATA Skin Sciences, Inc.). SOLESENCE, INC. runs the higher net margin — 1.3% vs 0.6%, a 0.7% gap on every dollar of revenue. On growth, SOLESENCE, INC. posted the faster year-over-year revenue change (-0.7% vs -3.0%). Over the past eight quarters, STRATA Skin Sciences, Inc.'s revenue compounded faster (17.3% CAGR vs 12.5%).
Strata Skin Sciences is an American medical device company focused on the design, development and commercialization of non-invasive tools to provide additional information to dermatologists during melanoma skin examinations.
SLSN vs SSKN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $12.5M | $9.3M |
| Net Profit | $163.0K | $58.0K |
| Gross Margin | 27.5% | 61.8% |
| Operating Margin | 1.5% | 5.3% |
| Net Margin | 1.3% | 0.6% |
| Revenue YoY | -0.7% | -3.0% |
| Net Profit YoY | 129.2% | 101.3% |
| EPS (diluted) | $0.00 | $0.14 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $12.5M | $9.3M | ||
| Q3 25 | $14.6M | $6.9M | ||
| Q2 25 | $20.4M | $7.7M | ||
| Q1 25 | $14.6M | $6.8M | ||
| Q4 24 | $12.6M | $9.6M | ||
| Q3 24 | $16.9M | $8.8M | ||
| Q2 24 | $13.0M | $8.4M | ||
| Q1 24 | $9.9M | $6.8M |
| Q4 25 | $163.0K | $58.0K | ||
| Q3 25 | $-1.1M | $-1.6M | ||
| Q2 25 | $2.7M | $-2.6M | ||
| Q1 25 | $80.0K | $-2.1M | ||
| Q4 24 | $-559.0K | $-4.6M | ||
| Q3 24 | $3.0M | $-2.1M | ||
| Q2 24 | $856.0K | $-91.0K | ||
| Q1 24 | $893.0K | $-3.4M |
| Q4 25 | 27.5% | 61.8% | ||
| Q3 25 | 23.1% | 60.4% | ||
| Q2 25 | 28.9% | 56.2% | ||
| Q1 25 | 23.1% | 53.5% | ||
| Q4 24 | 22.0% | 61.4% | ||
| Q3 24 | 36.2% | 60.1% | ||
| Q2 24 | 28.7% | 59.0% | ||
| Q1 24 | 36.3% | 45.6% |
| Q4 25 | 1.5% | 5.3% | ||
| Q3 25 | -5.4% | -16.9% | ||
| Q2 25 | 9.4% | -30.1% | ||
| Q1 25 | 1.8% | -25.0% | ||
| Q4 24 | -1.8% | -44.7% | ||
| Q3 24 | 19.0% | -18.2% | ||
| Q2 24 | 8.0% | -5.7% | ||
| Q1 24 | 11.3% | -42.7% |
| Q4 25 | 1.3% | 0.6% | ||
| Q3 25 | -7.7% | -23.4% | ||
| Q2 25 | 13.1% | -33.6% | ||
| Q1 25 | 0.5% | -31.2% | ||
| Q4 24 | -4.4% | -47.6% | ||
| Q3 24 | 18.1% | -23.6% | ||
| Q2 24 | 6.6% | -1.1% | ||
| Q1 24 | 9.0% | -49.8% |
| Q4 25 | $0.00 | $0.14 | ||
| Q3 25 | $-0.02 | $-0.36 | ||
| Q2 25 | $0.04 | $-0.62 | ||
| Q1 25 | $0.00 | $-0.51 | ||
| Q4 24 | $0.00 | $-2.01 | ||
| Q3 24 | $0.04 | $-0.51 | ||
| Q2 24 | $0.01 | $-0.03 | ||
| Q1 24 | $0.02 | $-0.10 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.3M | $7.9M |
| Total DebtLower is stronger | — | $15.3M |
| Stockholders' EquityBook value | $17.6M | $2.9M |
| Total Assets | $50.1M | $30.5M |
| Debt / EquityLower = less leverage | — | 5.28× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.3M | $7.9M | ||
| Q3 25 | $429.0K | $7.1M | ||
| Q2 25 | $4.1M | $6.0M | ||
| Q1 25 | $1.8M | $6.5M | ||
| Q4 24 | $1.4M | $7.3M | ||
| Q3 24 | $2.9M | $7.1M | ||
| Q2 24 | $2.4M | $5.5M | ||
| Q1 24 | $2.0M | $5.2M |
| Q4 25 | — | $15.3M | ||
| Q3 25 | — | $15.3M | ||
| Q2 25 | — | $15.0M | ||
| Q1 25 | — | $15.0M | ||
| Q4 24 | — | $15.0M | ||
| Q3 24 | — | $15.0M | ||
| Q2 24 | — | $15.0M | ||
| Q1 24 | — | $15.0M |
| Q4 25 | $17.6M | $2.9M | ||
| Q3 25 | $17.2M | $1.3M | ||
| Q2 25 | $18.2M | $532.0K | ||
| Q1 25 | $15.2M | $3.0M | ||
| Q4 24 | $14.9M | $5.0M | ||
| Q3 24 | $15.2M | $9.4M | ||
| Q2 24 | $11.9M | $9.5M | ||
| Q1 24 | $5.0M | $9.4M |
| Q4 25 | $50.1M | $30.5M | ||
| Q3 25 | $54.0M | $30.7M | ||
| Q2 25 | $60.0M | $29.5M | ||
| Q1 25 | $57.0M | $33.0M | ||
| Q4 24 | $50.0M | $34.9M | ||
| Q3 24 | $48.0M | $39.4M | ||
| Q2 24 | $40.8M | $38.8M | ||
| Q1 24 | $38.5M | $39.2M |
| Q4 25 | — | 5.28× | ||
| Q3 25 | — | 11.65× | ||
| Q2 25 | — | 28.20× | ||
| Q1 25 | — | 5.04× | ||
| Q4 24 | — | 3.02× | ||
| Q3 24 | — | 1.60× | ||
| Q2 24 | — | 1.58× | ||
| Q1 24 | — | 1.59× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.8M | $-239.0K |
| Free Cash FlowOCF − Capex | — | $-551.0K |
| FCF MarginFCF / Revenue | — | -5.9% |
| Capex IntensityCapex / Revenue | — | 3.4% |
| Cash ConversionOCF / Net Profit | 11.16× | -4.12× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-4.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.8M | $-239.0K | ||
| Q3 25 | $-2.5M | $-64.0K | ||
| Q2 25 | $-654.0K | $-1.9M | ||
| Q1 25 | $-7.2M | $-550.0K | ||
| Q4 24 | $2.2M | $703.0K | ||
| Q3 24 | $4.2M | $-302.0K | ||
| Q2 24 | $-565.0K | $591.0K | ||
| Q1 24 | $-3.9M | $-804.0K |
| Q4 25 | — | $-551.0K | ||
| Q3 25 | — | $-1.1M | ||
| Q2 25 | — | $-2.0M | ||
| Q1 25 | — | $-749.0K | ||
| Q4 24 | $-404.0K | $199.0K | ||
| Q3 24 | $2.8M | $-364.0K | ||
| Q2 24 | $-1.0M | $246.0K | ||
| Q1 24 | $-3.9M | $-1.5M |
| Q4 25 | — | -5.9% | ||
| Q3 25 | — | -15.6% | ||
| Q2 25 | — | -26.1% | ||
| Q1 25 | — | -11.0% | ||
| Q4 24 | -3.2% | 2.1% | ||
| Q3 24 | 16.6% | -4.1% | ||
| Q2 24 | -8.0% | 2.9% | ||
| Q1 24 | -39.9% | -22.6% |
| Q4 25 | — | 3.4% | ||
| Q3 25 | — | 14.7% | ||
| Q2 25 | — | 0.8% | ||
| Q1 25 | — | 2.9% | ||
| Q4 24 | 20.6% | 5.3% | ||
| Q3 24 | 8.3% | 0.7% | ||
| Q2 24 | 3.7% | 4.1% | ||
| Q1 24 | 0.9% | 10.7% |
| Q4 25 | 11.16× | -4.12× | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.25× | — | ||
| Q1 25 | -90.26× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.38× | — | ||
| Q2 24 | -0.66× | — | ||
| Q1 24 | -4.32× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
SLSN
Segment breakdown not available.
SSKN
| Dermatology Recurring Procedures | $6.1M | 65% |
| Dermatology Procedures Equipment | $3.2M | 35% |
